Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review
In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery. Both fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab combined with 5-fluorouracil, l-leucovorin, and irinotecan (FOLFIRI) proved ineffective against the disease. The patient was then treated with ensartinib, as the CAD-ALK fusion gene was detected by genomic analysis. The patient was initially treated with ensartinib monother...
Source: The Oncologist - February 21, 2024 Category: Cancer & Oncology Authors: Tingting Hu Jinbo Zhan Li Li Yan He Yun Lin Jingru Wang Haiming Yu Jianping Xiong Ziling Fang Jun Deng Shanshan Huang Xiaojun Xiang Source Type: research

Cancers, Vol. 16, Pages 857: Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial
In conclusion, the ASSO-LM1 trial is a hypothesis-generating study confirming the prognostic benefits of perioperative therapy with XELOX and bevacizumab in patients with metastatic colorectal cancer confined to the liver. (Source: Cancers)
Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Yawen Dong Jonas Santol Birgit Gruenberger Alfred Lenauer Friedrich Laengle Josef Thaler Gudrun Piringer Wolfgang Eisterer Angela Djanani Judith Stift Thomas Gruenberger Tags: Article Source Type: research

An innovative antibody fusion protein targeting PD-L1, VEGF and TGF- β with enhanced antitumor efficacies
Int Immunopharmacol. 2024 Feb 19;130:111698. doi: 10.1016/j.intimp.2024.111698. Online ahead of print.ABSTRACTImmunosuppressive pathways in the tumor microenvironment (TME) are inextricably linked to tumor progression. Mono-therapeutics of immune checkpoint inhibitors (ICIs, e.g. antibodies against programmed cell death protein-1/programmed cell death ligand-1, PD-1/PD-L1) is prone to immune escape while combination therapeutics tends to cause high toxicity and side effects. Therefore, using multi-functional molecules to target multiple pathways simultaneously is becoming a new strategy for cancer therapies. Here, we devel...
Source: International Immunopharmacology - February 20, 2024 Category: Allergy & Immunology Authors: Wenlu Fan Yonglu Chen Zhenxing Zhou Wenwen Duan Chengcheng Yang Shimei Sheng Yongwei Wang Xinru Wei Ying Liu Yanshan Huang Source Type: research

The effect of combination therapy with intravitreal bevacizumab and topical timolol –dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial
ConclusionOur findings support the short-term effectiveness of topical timolol –dorzolamide as adjunctive therapy to IVB injections in managing center-involving DME in terms of anatomical and visual outcomes. Trial registration: Clinicaltrials.gov NCT05083689 (October 19, 2021). (Source: International Ophthalmology)
Source: International Ophthalmology - February 20, 2024 Category: Opthalmology Source Type: research

Chitosan surface modification modulates the mucoadhesive, permeation and anti-angiogenic properties of gellan gum/bevacizumab nanoparticles
Int J Biol Macromol. 2024 Feb 17;263(Pt 1):130272. doi: 10.1016/j.ijbiomac.2024.130272. Online ahead of print.ABSTRACTBevacizumab (BVZ) was the first monoclonal antibody approved by the FDA and has shown an essential advance in the antitumor therapy of colorectal cancer (CRC), however, the systemic action of BVZ administered intravenously can trigger several adverse effects. The working hypothesis of the study was to promote the modulation of the mucoadhesion properties and permeability of the BVZ through the formation of nanoparticles (NPs) with gellan gum (GG) with subsequent surface modification with chitosan (CS). NPs ...
Source: International Journal of Biological Macromolecules - February 19, 2024 Category: Biochemistry Authors: Suzana Gon çalves Carvalho Felipe Falc ão Haddad Aline Martins Dos Santos Cau ê Benito Scarim Leonardo Miziara Barboza Ferreira Andr éia Bagliotti Meneguin Marlus Chorilli Maria Palmira Daflon Gremi ão Source Type: research

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research

Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study
CONCLUSIONS: Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.PMID:38372727 | DOI:10.1158/1078-0432.CCR-23-3162 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 19, 2024 Category: Cancer & Oncology Authors: Hanmei Lou Hongbing Cai Xin Huang Guiling Li Li Wang Fei Liu Wenjing Qin Ting Liu Wei Liu Zhongmin Maxwell Wang Baiyong Li Yu Xia Jing Wang Source Type: research

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research

Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study
CONCLUSIONS: Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.PMID:38372727 | DOI:10.1158/1078-0432.CCR-23-3162 (Source: Cancer Control)
Source: Cancer Control - February 19, 2024 Category: Cancer & Oncology Authors: Hanmei Lou Hongbing Cai Xin Huang Guiling Li Li Wang Fei Liu Wenjing Qin Ting Liu Wei Liu Zhongmin Maxwell Wang Baiyong Li Yu Xia Jing Wang Source Type: research

Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2024 Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research

Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study
CONCLUSIONS: Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.PMID:38372727 | DOI:10.1158/1078-0432.CCR-23-3162 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 19, 2024 Category: Cancer & Oncology Authors: Hanmei Lou Hongbing Cai Xin Huang Guiling Li Li Wang Fei Liu Wenjing Qin Ting Liu Wei Liu Zhongmin Maxwell Wang Baiyong Li Yu Xia Jing Wang Source Type: research

The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab
ConclusionIn order to stratify the risk for developing ICH before the initiation of bevacizumab, we recommend to assess for the presence of cerebral macrobleeding as it is associated with ICH development. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 19, 2024 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 16, Pages 838: Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
Jang Won Young Tak Real-world data regarding treatment with atezolizumab plus bevacizumab in high-risk patients with advanced HCC are lacking. In this multicenter retrospective cohort study, a total of 215 patients with advanced HCC received atezolizumab plus bevacizumab treatment at four tertiary hospitals. High-risk patients were those with grade Vp4 portal vein thrombus, bile duct invasion, or more than 50% liver infiltration. In total, 98 (45.6%) were the high-risk population, 186 (86.5%) were considered to be Child–Pugh class A, and 128 (59.5%) had previously received neoadjuvant or concomitant ra...
Source: Cancers - February 19, 2024 Category: Cancer & Oncology Authors: Sang Youn Hwang Hyun Young Woo Jeong Heo Hyung Jun Kim Young Joo Park Ki Youn Yi Yu Rim Lee Soo Young Park Woo Jin Chung Byoung Kuk Jang Won Young Tak Tags: Article Source Type: research

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
ConclusionPatients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 19, 2024 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Oncologist. 2024 Feb 16:oyae007. doi: 10.1093/oncolo/oyae007. Online ahead of print.ABSTRACTWe performed a systematic literature review to identify and summarize data from studies reporting clinical efficacy and safety outcomes for trifluridine/tipiracil (FTD/TPI) combined with other antineoplastic agents in advanced cancers, including metastatic colorectal cancer (mCRC). We conducted a systematic search on May 29, 2021, for studies reporting one or more efficacy or safety outcome with FTD/TPI-containing combinations. Our search yielded 1378 publications, with 38 records meeting selection criteria: 35 studies of FTD/TPI-co...
Source: The Oncologist - February 17, 2024 Category: Cancer & Oncology Authors: Kohei Shitara Alfred Falcone Marwan G Fakih Ben George Raghav Sundar Sandip Ranjan Eric Van Cutsem Source Type: research